Skip to main content

Holiday schedule

Our Patient Service Centers will be closed on Wednesday, December 25, 2024 in observance of Christmas and Wednesday, January 1, 2025 in observance of New Year's Day. Have a healthy, happy holiday.

Hide
Quest Diagnostics

Guideline-based Hereditary Cancer Panel

Test code(s) 38611

This test is used to help identify individuals with a hereditary predisposition to cancer. It may be used for individuals with a personal or family history of cancer that does not clearly point to a specific cancer syndrome. This multigene panel can also identify individuals with a hereditary cancer predisposition when the clinical suspicion remains high despite a negative result on a single-gene/syndrome genetic test.

This panel analyzes 32 genes: APC, ATM, AXIN2, BARD1, BMPR1A, BRCA1, BRCA2, BRIP1, CDH1, CDK4, CDKN2A (p16, p14), CHEK2, EPCAM, GREM1, HOXB13, MLH1, MSH2, MSH3, MSH6, MUTYH, NF1, NTHL1, PALB2, POLD1, POLE, PMS2, PTEN, RAD51C, RAD51D, SMAD4, STK11, and TP53.

Generally, this test may be indicated for individuals with

  • A personal history of cancer who have tested negative for a single gene or syndrome, but whose personal or family history remains strongly suggestive of an inherited susceptibility

  • A personal and/or family history of several different types of cancer that do not seem to fit a particular hereditary cancer syndrome 

Informed consent is required, and genetic counseling is recommended. Whenever possible, consider testing the person in the family with the youngest age at diagnosis related to genetic testing.

If a familial mutation has been detected by sequencing or deletion/duplication studies, the Hereditary Cancer Single Site(s) test (test code 93945) may be considered. The family member’s official test results must be available for laboratory review. For more information, please visit our website QuestHereditaryCancer.com. To discuss a family history with a Quest genetic counselor, please call Quest Genomics Client Services at 1.866.GENE.INFO (1.866.436.3463).

To obtain more information or to discuss a family history with a Quest genetic counselor, please call Quest Genomics Client Services at 1.866.GENE.INFO (1.866.436.3463).

The right time is different for every individual. An individual’s current medical status, treatment or screening plan, personal experience with cancer, family history, and general readiness for genetic information all influence the decision to proceed with testing. Having an open dialogue with individuals about these topics can assist with shared decision-making. Additionally, you can consider referring individuals to a clinical genetic counselor for a thorough review of their family history and discussion of testing options. Find a local genetic counselor by visiting FindAGeneticCounselor.com.  

Upon receipt of a fully completed order, our team will verify coverage with your patient’s healthcare insurance plan and estimate their likely out-of-pocket responsibility. If your patient’s estimated responsibility is over $100, we will notify you and/or your patient prior to test initiation to discuss options for continuation or cancellation of the test. Please note that orders lacking complete information will not be processed.  

On average, results will be completed 14 to 21 days after receipt of the sample in the laboratory if the family history form and order are complete and the health plan does not require preauthorization. Turnaround time may vary based on delays caused by incomplete orders or insurance authorizations.

Individuals with a positive result have a pathogenic or likely pathogenic variant(s) detected in one or more of the genes included in this panel. A positive result does not mean that an individual has cancer. Specific risk information will be provided in the result report, and you can visit our website at www.QuestHereditaryCancer.com for more information.

The National Comprehensive Cancer Network® (NCCN) provides up-to-date surveillance and management recommendations1-4 for individuals with a positive result. 

A negative result means that a pathogenic or likely pathogenic variant was not detected in any of the genes included in this panel. For more information regarding specific genetic variants analyzed in this assay, please refer to the methods and limitations section of the genetic testing report. Implications of this result depend on the situation:

Individual with previously diagnosed cancer: An individual’s risk of recurrence or a related new cancer is based on their personal and family histories of cancer. In some instances, it may be appropriate to test for other hereditary forms of cancer. Please call Quest Genomics Client Services at 1.866.GENE.INFO (1.866.436.3463) to discuss possible additional studies with a genetic counselor.

Individual without previously diagnosed cancer but with a family history of cancer: An individual’s risk of cancer is based on their personal and family histories. Testing an affected family member may further inform this risk assessment. In some instances, it may be appropriate to test for other hereditary forms of cancer. Please call Quest Genomics Client Services at 1.866.GENE.INFO (1.866.436.3463) to discuss possible additional studies with a genetic counselor.

A VUS result means that the variant has not been previously described in the literature or that the clinical significance is unclear based upon currently available evidence. Medical management decisions should be based on personal and family history. Family studies may help to learn more about the clinical significance of this variant.

The classification and interpretation of the variant(s) identified reflect the current state of Quest’s understanding at the time of this report. Variant classification and interpretation are subject to professional judgment and may change for a variety of reasons including, but not limited to, updates in classification guidelines and availability of additional scientific and clinical information. It is important to check in with the laboratory annually for variant updates because new information regarding the variant and classification may become available over time.

Please, visit QuestDiagnostics.com/VariantIQ for information about variant classification. If you have questions, please call Quest Genomics Client Services at 1.866.GENE.INFO (1.866.436.3463) to speak with a genetic counselor.

This test cannot detect all causes of hereditary predisposition to cancer. This test is limited to the genes on the panel and does not analyze genes associated with hereditary cancer other than those specified. This test does not examine each and every gene region that is associated with hereditary cancer, so the test cannot detect variants in those unexamined gene regions. There may be other genetics tests that are also appropriate depending on a patient’s personal or family history of cancer. If you have questions or would like to discuss test options, please call Quest Genomics Client Services at 1.866.GENE.INFO (1.866.436.3463) to speak with a genetic counselor.

In addition, the effect of rare or novel variants on cancer risk may remain unclear despite technical and clinical advances. Although rare, false positive or false negative results may occur for several reasons. Therefore, results should be interpreted in the context of clinical findings, relevant history, and other laboratory data. In some situations, additional genetic testing may be appropriate. A genetic counselor or other qualified healthcare professional can help explain test results and what they mean for a patient and family members.

A person’s cancer risks should be based on their own medical history and family history of cancer. A doctor, genetic counselor, or other qualified healthcare professional can help to estimate this risk. A team of specialized Quest genetic counselors or geneticists are available to speak with healthcare providers about test results by calling 1.866.GENE.INFO. Patients can access a directory of independent genetic counselors at FindAGeneticCounselor.com.  

References

  1. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®). Genetic/familial high-risk assessment: breast, ovarian, and pancreatic. Version 3.2023. Published February 13, 2023. https://www.nccn.org/
  2. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines). Genetic/familial high-risk assessment: colorectal. Version 2.2022. Published December 7, 2022. https://www.nccn.org
  3. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines). Cutaneous melanoma. Version 1.2023. Published December 22, 2022. https://www.nccn.org
  4. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines). Prostate cancer early detection. Version 1.2023. Published January 9, 2023. https://www.nccn.org

 

This FAQ is provided for informational purposes only and is not intended as medical advice. Test selection and interpretation, diagnosis, and patient management decisions should be based on the clinician’s education, clinical expertise, and assessment of the patient.


Document FAQS.237 Version 1

Version 1: Effective 04/21/2023 to present

Version 0: Effective 01/25/2021 to 04/21/2023

Our company

Quest® is the brand name used for services offered by Quest Diagnostics Incorporated and its affiliated companies. Quest Diagnostics Incorporated and certain affiliates are CLIA-certified laboratories that provide HIPAA-covered services.  Other affiliates operated under the Quest® brand, such as Quest Consumer Inc., do not provide HIPAA-covered services. 

 

Quest®, Quest Diagnostics®, any associated logos, and all associated Quest Diagnostics registered or unregistered trademarks are the property of Quest Diagnostics. All third-party marks—® and ™—are the property of their respective owners. © 2024 Quest Diagnostics Incorporated. All rights reserved. Image content features models and is intended for illustrative purposes only.